Odyssey Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of next-generation precision medicines for inflammatory diseases and cancer. Founded in 2021 and headquartered in Boston, Massachusetts, the company integrates advanced technologies in drug discovery, including high-throughput screening, structural biology, and artificial intelligence, to target complex biological pathways that were previously considered undruggable. Odyssey's platform aims to create a diverse pipeline of small molecules and protein therapeutics that address significant unmet medical needs. The company's strategy involves a multi-disciplinary approach, combining deep expertise in molecular biology with computational chemistry to accelerate the transition from target identification to clinical development. Their research focuses on modulating the immune system and targeting specific drivers of oncogenesis to provide more effective and safer treatments. Led by a team of experienced drug hunters and scientists, including founder and CEO Gary D. Glick, Odyssey Therapeutics has raised substantial capital to support its ambitious portfolio. By leveraging its integrated technology stack and specialized expertise, the company seeks to redefine the standards of care for patients suffering from life-threatening and chronic conditions through the delivery of highly potent and selective therapeutic candidates.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!